Rhino-orbital-cerebral mucormycosis is a rapidly progressive, angioinvasive fungal infection and a medical/surgical emergency with mortality rates of 50–80%, rising to >90% with disseminated or cerebral involvement. [1-2] Early recognition and immediate multidisciplinary intervention are the most critical determinants of survival. [3]
The following figure from a 2026 NEJM review illustrates the clinical and diagnostic spectrum of mucormycosis, including periorbital cellulitis, necrotic eschars, palatal necrosis, sinus CT findings, and the characteristic broad, ribbon-like, pauci-septate hyphae on histopathology:
1. History
- Key HPI questions: Onset and progression of facial pain, nasal congestion/discharge, headache, visual changes (diplopia, blurred vision, vision loss), facial numbness, tooth pain
- Symptom characterization: Unilateral facial pain/swelling → periorbital edema → visual changes; progression over hours to days [1][4]
- Timing: Rapid progression is the hallmark — symptoms can evolve from mild sinusitis to orbital/cerebral involvement within 24–72 hours [1]
- Triggers: Recent DKA episode, recent high-dose corticosteroid use, recent chemotherapy, recent COVID-19 illness [1]
- Associated symptoms: Fever, bloody/dark nasal discharge, anosmia, odontogenic pain, seizures, altered mental status [1][5]
- Important negatives: Absence of trauma (rules out cutaneous form), absence of cough/hemoptysis (rules out pulmonary form)
2. Alarm Features
- Black necrotic eschar on nasal mucosa, turbinates, or palate — pathognomonic for angioinvasive fungal infection [1][3]
- Periorbital cellulitis, proptosis, ophthalmoplegia — indicates orbital extension [1][6]
- Vision loss (especially no light perception) — associated with higher mortality [2]
- Cranial nerve palsies (CN III, IV, V1, V2, VI) — suggests cavernous sinus involvement [1]
- Impaired V2 nerve function — independently associated with higher mortality [2]
- Altered mental status, seizures, focal neurologic deficits — indicates cerebral extension, a surgical emergency [1][4]
- Rapid clinical deterioration despite antibiotics in an immunocompromised or diabetic patient [3]
3. Medications
- Relevant contributors:
- Prolonged high-dose glucocorticoids — major risk factor [1]
- Voriconazole prophylaxis — NOT active against Mucorales and may select for breakthrough mucormycosis [1]
- Ibrutinib, CAR-T therapy — recently identified risk factors [1]
- Deferoxamine (iron chelator) — increases iron availability to Mucorales; contraindicated [7]
- First-line treatment: Liposomal amphotericin B 5–10 mg/kg/day IV (10 mg/kg/day if CNS involvement) [3]
- Alternatives/step-down: Isavuconazole (FDA-approved for mucormycosis) or posaconazole delayed-release tablets — for renal failure, intolerance, or step-down maintenance [3][8-9]
- Contraindicated antifungals: Echinocandins, fluconazole, itraconazole, voriconazole — NO activity against Mucorales [1]
- Key caution: Monitor renal function closely on amphotericin B; hypokalemia is the most common adverse effect (50–70%) [5][10]
4. Diet
- Acute phase: NPO if surgical debridement planned; otherwise standard nutrition support
- DKA management: Aggressive IV fluid resuscitation, insulin infusion, electrolyte correction — metabolic correction is a pillar of treatment [1]
- Long-term: Strict glycemic control (HbA1c <8%) — elevated HbA1c is a significant mortality predictor [11]
- Iron supplementation: Avoid unnecessary iron supplementation, as iron overload states promote Mucorales growth [1][7]
5. Review of Systems
- HEENT: Nasal congestion, bloody/purulent discharge, facial pain/swelling, tooth pain, vision changes, eye pain, tearing
- Neurologic: Headache, facial numbness (V2 distribution), diplopia, seizures, altered mental status, focal weakness
- Pulmonary: Cough, dyspnea, hemoptysis, pleuritic chest pain (screen for sinopulmonary extension) [1]
- Constitutional: Fever, malaise, weight loss
- GI: Nausea, vomiting (may indicate DKA or GI mucormycosis)
- Skin: Any necrotic wounds or eschars at other sites (disseminated disease) [1]
6. Collateral History and Family History
- Collateral: Confirm diabetes control history, recent steroid use (dose and duration), recent hospitalization, COVID-19 history, chemotherapy regimen, transplant status and immunosuppression regimen
- Family history: Diabetes mellitus (type 1 or 2), hematologic malignancies
- Social context: IV drug use (risk for disseminated/endocarditis-associated mucormycosis), occupational exposure to soil/construction (environmental Mucorales exposure) [1]
7. Risk Factors
- Diabetes mellitus (especially with DKA) — the predominant risk factor for ROCM [1][12]
- Hematologic malignancies and prolonged neutropenia [1][3]
- Hematopoietic cell transplantation (median onset ~135 days post-HCT) [6]
- Solid organ transplantation [1]
- Prolonged high-dose glucocorticoid use [1]
- COVID-19 (particularly with concurrent DM and steroid use) [1][13]
- Iron overload states and deferoxamine therapy [1]
- Severe aplastic anemia [1]
- HbA1c >8%, age >60 years — independent mortality predictors [11]
8. Differential Diagnosis
- Invasive aspergillosis — most important mimic; septate, dichotomously branching hyphae (vs. broad, pauci-septate in Mucorales); galactomannan-positive [1][14]
- Bacterial orbital cellulitis — typically responds to antibiotics; lacks necrotic eschars
- Orbital apex syndrome from other causes (tumor, granulomatosis with polyangiitis, sarcoidosis)
- Cavernous sinus thrombosis — may coexist with ROCM; similar cranial nerve findings
- Invasive fusariosis or scedosporiosis — other angioinvasive molds; require culture/histopath for differentiation [1]
- Squamous cell carcinoma of the sinuses — can mimic destructive sinus disease
- Granulomatosis with polyangiitis (GPA) — midline destructive lesion, ANCA-positive
- Distinguishing pearl: Negative galactomannan and β-D-glucan in the setting of angioinvasive mold infection strongly favors mucormycosis over aspergillosis [6][15]
9. Past Medical History
- Critical to elicit: Diabetes (type, duration, control, DKA history), hematologic malignancy, transplant history, HIV/AIDS, chronic steroid use
- Previous episodes: Recurrence is possible, especially if underlying immunosuppression persists
- Surgical history: Prior sinus surgery, orbital surgery, dental procedures
- Chronic illnesses: Chronic kidney disease (affects amphotericin B dosing), liver disease, iron overload conditions
10. Physical Exam
- Vital signs: Fever (present in ~70% of cases), tachycardia; check for Kussmaul respirations (DKA) [5]
- Nasal exam: Black necrotic eschar on turbinates or septum, purulent/bloody discharge, septal ulceration [1][5]
- Oral exam: Palatal ischemia or necrosis (especially with maxillary sinus involvement), molar/premolar tenderness [1]
- Orbital exam: Periorbital edema/erythema, proptosis, chemosis, ophthalmoplegia, ptosis, decreased visual acuity, afferent pupillary defect [2][5]
- Cranial nerves: Test CN II–VI carefully — deficits suggest cavernous sinus invasion [1][6]
- Neurologic: Mental status, focal deficits, signs of meningismus
- Skin: Inspect for necrotic eschars elsewhere (disseminated disease)
- Key finding: Necrotic lesions in oral cavity/sinuses found in 87% of cases in one series [5]
11. Lab Studies
- Recommended labs:
- BMP (glucose, creatinine, potassium — baseline for amphotericin B monitoring)
- CBC with differential (assess for neutropenia)
- HbA1c
- ABG/VBG (assess for metabolic acidosis/DKA)
- Blood glucose, serum ketones
- LFTs, coagulation studies
- Serum iron studies (iron overload assessment)
- Expected abnormalities: Hyperglycemia, metabolic acidosis, elevated anion gap (DKA), hypokalemia (from amphotericin B) [5]
- Rule-out labs: Serum galactomannan and β-D-glucan are negative in mucormycosis (Mucorales lack these cell wall components) — a negative result in the setting of suspected invasive mold infection should raise suspicion for mucormycosis [6][15]
- Emerging diagnostics: Serum Mucorales qPCR (75–80% sensitivity; positive in 91% of hematogenous cases) — increasingly available commercially (MucorGenius, MycoGENIE) [6][16]
- Monitoring: Renal function and potassium at least every other day during amphotericin B therapy [10][15]
12. Imaging
- First-line: CT of paranasal sinuses (with contrast) — assess for mucosal thickening, bony erosion, peri-antral fat infiltration, orbital extension [3][17]
- Gold standard for orbital/cerebral involvement: MRI with gadolinium — substantially greater sensitivity than CT for detecting orbital soft tissue invasion, cavernous sinus involvement, meningeal enhancement, perineural spread, and cerebral extension [3][18]
- Important findings:
- Sinus opacification with bony erosion
- Orbital fat stranding, extraocular muscle thickening
- Cavernous sinus enhancement/thrombosis
- Meningeal enhancement (cerebral extension)
- Frontal lobe infarction (from internal carotid artery invasion) [1][18]
- Critical caveat: CT and MRI may be unremarkable in early disease — a normal scan does NOT rule out mucormycosis; repeat imaging and endoscopy are essential [1]
- Staging: Once ROCM is confirmed, obtain chest CT to evaluate for pulmonary involvement [1]
- Follow-up: Weekly CT/MRI recommended in unstable patients [3]
13. Special Tests
- Nasal endoscopy with biopsy — the most critical diagnostic procedure; brush biopsy of ulcerations and necrotic eschars [1][3]
- Histopathology: PAS and GMS stains showing broad (7–15 μm), ribbon-like, pauci-septate hyphae with non-dichotomous (right-angle) branching — pathognomonic [1]
- Direct microscopy: KOH wet mount or calcofluor/Blankophor fluorescence staining for rapid identification [1]
- Culture: Sabouraud's glucose agar at 25–37°C; grows rapidly but culture is positive in only ~50% of cases [1][16]
- MALDI-TOF MS: Rapid species identification from culture isolates [1]
- Molecular: Mucorales-specific PCR (serum, BAL, tissue) — emerging as a key early diagnostic tool [1][6][16]
- Metagenomic cell-free DNA sequencing: Promising but not yet validated for routine use [1]
14. ECG
- Indications: Baseline ECG before initiating amphotericin B (monitor for electrolyte-related arrhythmias, especially hypokalemia-induced QT prolongation)
- If isavuconazole is used: Note that isavuconazole can shorten the QTc interval — contraindicated in patients with familial short QT syndrome [3]
- Monitor for: Hypokalemia-related changes (U waves, ST depression, T wave flattening) during amphotericin B therapy
15. Assessment
- Clinical summary: ROCM is a medical and surgical emergency requiring immediate multidisciplinary intervention. The five pillars of management are: (1) early detection, (2) prompt antifungal therapy, (3) surgical debridement, (4) reversal of immunodeficiency, and (5) correction of metabolic abnormalities. [1]
- Severity stratification:
- Isolated sinonasal: survival ~82% [19]
- Rhino-orbital: intermediate prognosis
- Rhino-orbito-cerebral: survival 27% (lowest) [19]
- Intracranial extension: mortality 71% [19]
- Typical presentation: Diabetic patient in DKA with unilateral facial pain/swelling, bloody nasal discharge, periorbital edema progressing to proptosis and vision loss [4][12]
- Atypical presentations: May present as isolated headache, dental pain, or fever of unknown origin in neutropenic patients [1]
- Complications: Cavernous sinus thrombosis, internal carotid artery invasion with stroke, frontal lobe abscess, orbital exenteration, disseminated disease [1][18]
16. Treatment Plan
Initial stabilization
- ABCs, IV access, continuous monitoring
- Correct DKA aggressively: IV fluids, insulin drip, electrolyte repletion [1]
- Rapidly reduce glucocorticoid dose to the lowest effective dose [1]
Antifungal therapy (start empirically if high suspicion — do not wait for culture):
- Liposomal amphotericin B 5 mg/kg/day IV (standard dose) [3]
- Escalate to 10 mg/kg/day if CNS involvement (based on animal models and clinical data) [3][15]
- Alternative if renal failure/intolerance: Isavuconazole (loading: 200 mg IV/PO q8h × 6 doses, then 200 mg daily) or posaconazole delayed-release tablets (300 mg BID day 1, then 300 mg daily) [3][9]
- Duration: Continue until imaging resolution and immune reconstitution; no fixed duration — typically 4–6 weeks minimum of primary therapy, often longer [3][15]
Surgical intervention
- Urgent ENT/surgical consultation for debridement — perform as soon as feasible, in parallel with antifungal therapy [3][19]
- Endoscopic sinus debridement with removal of all necrotic tissue
- Second-look surgery at day 7 recommended to reassess margins [20]
- Orbital exenteration if globe is non-viable (NLP vision) with extensive orbital involvement — all exenteration patients survived in one 3-year cohort [2]
- Combined surgical + medical therapy reduces mortality from 88% to 32% compared to antifungals alone [19]
Adjunctive measures
- G-CSF or GM-CSF if neutropenic [1]
- Granulocyte transfusions in selected cases pending neutrophil recovery [1]
- Hyperbaric oxygen — may be beneficial in selected diabetic patients with sino-orbital/rhinocerebral disease [1]
- Deferasirox is NOT recommended (randomized pilot trial showed no benefit) [21]
Step-down/maintenance therapy
17. Disposition
- All suspected ROCM patients require immediate hospital admission, typically to an ICU or step-down unit [3]
- Admission criteria: Any patient with suspected invasive fungal sinusitis in the setting of immunosuppression or uncontrolled diabetes
- ICU indications: DKA, hemodynamic instability, altered mental status, cerebral involvement, post-operative monitoring after extensive debridement
- Specialist consultation triggers (all urgent):
- Infectious disease — antifungal management
- ENT/otolaryngology — endoscopic evaluation and surgical debridement
- Ophthalmology — orbital assessment, visual acuity monitoring
- Neurosurgery — if intracranial extension
- Endocrinology — DKA/glycemic management
- Discharge criteria: Clinical stability, resolving imaging, transition to oral step-down antifungal therapy, controlled underlying condition, reliable outpatient follow-up established
- ROCM is never an outpatient diagnosis — there is no role for observation or discharge from the ED [4]
18. Follow Up / Return Precautions
- Follow-up timing: Weekly imaging (CT or MRI) during active treatment; ENT endoscopic reassessment at 1–2 week intervals initially [3]
- Duration of antifungal therapy: Continue until complete resolution on imaging AND immune reconstitution — often months [3]
- Long-term monitoring: Renal function, electrolytes, hepatic function during prolonged antifungal therapy; ophthalmologic follow-up for visual outcomes
- Symptoms requiring immediate reassessment:
- New or worsening facial pain, swelling, or numbness
- Any visual changes (blurring, diplopia, vision loss)
- New headache, confusion, seizures, or focal neurologic deficits
- Fever recurrence
- Patient counseling:
- This is a life-threatening infection requiring prolonged treatment
- Strict glycemic control is essential to prevent recurrence
- Functional and cosmetic sequelae (vision loss, facial disfigurement) may be permanent
- Recovery is slow — imaging improvement in mucormycosis takes longer than in other fungal infections [15]
- Expected recovery: Partial or complete response typically achieved by 4–6 weeks of primary therapy, but total treatment duration is often months; recurrence is possible if immunosuppression persists [3][15]
References
1. Mucormycosis. — Kontoyiannis DP, Walsh TJ. The New England Journal of Medicine. 2026.
2. Survival and Prognostic Factors in Rhino-Orbito-Cerebral Mucormycosis: A 3-Year Cohort Study. — Zia Z, Sajadi MJ, Bazrafshan H, Khademi B, Janipour M. Scientific Reports. 2025.
3. Global Guideline for the Diagnosis and Management of Mucormycosis: An Initiative of the European Confederation of Medical Mycology in Cooperation With the Mycoses Study Group Education and Research Consortium. — Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. The Lancet. Infectious Diseases. 2019.
4. Rhino-Orbital Cerebral Mucormycosis in a Diabetic Patient: An Emergency Medicine Case Report. — Sweet R, Hovenden M, Harvey CE, Peterson W, Lott I. The Journal of Emergency Medicine. 2023.
5. Retrospective Evaluation of Mucormycosis Cases at a Tertiary Care Center Between 2000 and 2020 in Türkiye. — Öztürk Belik H, Heper Y, Kazak E, et al. Mycopathologia. 2026.
6. American Society of Transplantation and Cellular Therapy Series: #8-Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients. — Douglas AP, Lamoth F, John TM, et al. Transplantation and Cellular Therapy. 2025.
7. Mucormycosis in 2023: An Update on Pathogenesis and Management. — Alqarihi A, Kontoyiannis DP, Ibrahim AS. Frontiers in Cellular and Infection Microbiology. 2023.
8. FDA Orange Book. — FDA Orange Book. 2026.
9. Part 2: Mucormycosis: Focus on Therapy. — Lynch JP, Zhanel GG. Expert Review of Anti-Infective Therapy. 2023.
10. Prevention and Treatment of Cancer-Related Infections. — Updated 2026-03-11. National Comprehensive Cancer Network.
11. Analysis of COVID-19-associated Rhino-Orbital-Cerebral Mucormycosis Patients in a Tertiary Care Center in Northern India. — Yadav H, Sen S, Nath T, et al. Indian Journal of Ophthalmology. 2022.
12. Mucormycosis. — Czech MM, Cuellar-Rodriguez J. Infectious Disease Clinics of North America. 2025.
13. COVID-19 Associated Mucormycosis in Assiut University Hospitals: A Multidisciplinary Dilemma. — Farghly Youssif S, Abdelrady MM, Thabet AA, et al. Scientific Reports. 2022.
14. CT Findings for Differentiating Pulmonary Mucormycosis From Invasive Pulmonary Aspergillosis, Prior to Invasive Procedure Such as a Biopsy or Surgery: A 22-Year Single-Center Experience. — Jang HM, Kim MY, Lim SY, et al. Mycoses. 2025.
15. Definition, Diagnosis, and Management of COVID-19-associated Pulmonary Mucormycosis: Delphi Consensus Statement From the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. — Muthu V, Agarwal R, Patel A, et al. The Lancet. Infectious Diseases. 2022.
16. The Diagnosis of Mucormycosis by PCR in Patients at Risk: A Systematic Review and Meta-Analysis. — Brown L, Tschiderer L, Alanio A, et al. EClinicalMedicine. 2025.
17. Lung and Sinus Fungal Infection Imaging in Immunocompromised Patients. — Lamoth F, Prakash K, Beigelman-Aubry C, Baddley JW. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2024.
18. Multicenter Analysis of General Presentations and Imaging Features in Cerebral MUCORmycosis (MAGICMUCOR): Towards Different Entities. — de La Porte C, Provost C, Coste A, et al. Medical Mycology. 2025.
19. Impact of Anatomical Extent and Combined Surgical-Medical Therapy on Survival in Sinonasal and Rhino-Orbito-Cerebral Mucormycosis: A 14-Year Retrospective ENT Cohort. — Kozan G, Dedeoğlu S, Ayral M, Akdağ M. Journal of Clinical Medicine. 2025.
20. Systematic Surgical Reassessment Combined With Liposomal Amphotericin B: The MICA Protocol. — Gervais M, Aubertin M, Verillaud B, et al. Acta Oto-Laryngologica. 2026.
21. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis, Prevention, and Treatment of Invasive Fungal Diseases in Paediatric Patients With Cancer or Allogeneic Haemopoietic Stem-Cell Transplantation. — Groll AH, Castagnola E, Cesaro S, et al. The Lancet. Oncology. 2014.
22. Rhino-Orbito-Cerebral Mucormycosis in New-Onset Type 1 Diabetes Mellitus: A Case-Based Short Review. — Sharifi I, Razzeto A, Sacco SB, et al. The American Journal of the Medical Sciences. 2026.